@article{fdi:010079227,
  title = {{P}rojected number of people with onchocerciasis-loiasis coinfection in {A}frica, 1995 to 2025},
  author = {{V}inkeles {M}elchers, {N}.{V}.{S}. and {C}offeng, {L}.{E}. and {B}oussinesq, {M}ichel and {P}edrique, {B}. and {P}ion, {S}{\'e}bastien and {T}ekle, {A}.{H}. and {Z}oure, {H}.{G}.{M}. and {W}anji, {S}. and {R}emme, {J}.{H}. and {S}tolk, {W}.{A}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground : {O}nchocerciasis elimination through mass drug administration ({MDA}) is hampered by coendemicity of {L}oa loa, as people with high {L}. loa microfilariae (mf) density can develop serious adverse events ({SAE}s) after ivermectin treatment. {W}e assessed the geographical overlap of onchocerciasis and loiasis prevalence and estimated the number of coinfected individuals at risk of post-ivermectin {SAE}s in {W}est and {C}entral {A}frica from 1995 to 2025. {M}ethods : {F}ocusing on regions with suspected loiasis transmission in 14 countries, we overlaid precontrol maps of loiasis and onchocerciasis prevalence to calculate precontrol prevalence of coinfection by 5 km2 × 5 km2 pixel, distinguishing different categories of {L}. loa mf intensity. {U}sing statistical and mathematical models, we predicted prevalence of both infections and coinfection for 2015 and 2025, accounting for the impact of {MDA} with ivermectin. {R}esults : {T}he number of people infected with onchocerciasis was predicted to decline from almost 19 million in 1995 to 4 million in 2025. {O}f these, 137 000 people were estimated to also have {L}. loa hypermicrofilaremia (>-20 000 {L}. loa mf/m{L}) in 1995, declining to 31 000 in 2025. {I}n 2025, 92.8% of coinfected cases with loiasis hypermicrofilaremia are predicted to live in hypoendemic areas currently not targeted for {MDA}. {C}onclusions : {L}oiasis coinfection is a major concern for onchocerciasis elimination in {A}frica. {W}e predict that under current strategies, at least 31 000 coinfected people still require treatment for onchocerciasis in 2025 while being at risk of {SAE}s, justifying continued efforts in research and development for safer drugs and control strategies.},
  keywords = {{AFRIQUE} {CENTRALE} ; {CAMEROUN} ; {REPUBLIQUE} {DEMOCRATIQUE} {DU} {CONGO}},
  booktitle = {},
  journal = {{C}linical {I}nfectious {D}iseases},
  volume = {70},
  numero = {11},
  pages = {2281--2289},
  ISSN = {1058-4838},
  year = {2020},
  DOI = {10.1093/cid/ciz647},
  URL = {https://www.documentation.ird.fr/hor/fdi:010079227},
}